Lead the design, buildout, and execution of upstream and downstream capabilities within our Biologics Research organization to expand what’s possible for patients with serious diseases.
Compensation
Pay Range:
$185,000.00-252,500.00 Annual
Responsibilities
Build, lead, and mentor a high-performing research bioprocess development team
Establish a collaborative, accountable, and scientifically rigorous team culture
Set priorities and allocate resources across multiple concurrent programs
Design and oversee the buildout of new state-of-the-art research bioprocess development laboratories
Define equipment strategy and select platforms for upstream processing (USP) and downstream processing (DSP)
Requirements
PhD in chemical engineering, biochemical engineering, biology, or related field
The salary range for this position is: $146,540.00 - $189,640.00. Gilead considers a variety of factors when determining base compensation, including experience, qualifications, and geographic location. These considerations mean actual compensation will vary. This position may also be eligible for a discretionary annual bonus, discretionary stock-based long-term incentives (eligibility may vary based on role), paid time off, and a benefits package.
Responsibilities
Optimize and characterize cell culture processes to supply pivotal trials and enable commercialization for monoclonal antibodies, multi-specifics, and novel modalities.
Lead and/or support entire lifecycle of pivotal activities including process risk assessment, process characterization, preparation of all supporting documentation/reports toward BLA filing, provide support to ensure successful process performance qualifications (PPQ), and author relevant sections of BLA.
Lead and/or support technology transfer, person-in-plant, and investigation activities in partnership with the global manufacturing sciences and technologies (MSAT) group.
Design experiments and perform hands‑on cell culture operations in shake flasks, ambr15, ambr250, bench‑scale bioreactors, and novel cell culture platforms.
Provide support to pilot plant operation for up to 500 L.
Lead strategy and execution of biologics drug substance programs at the Rahway, New Jersey site.
Compensation
$173,200.00 - $272,600.00
Responsibilities
Direct strategy and execution of biologics drug substance programs
Lead cross‑functional CMC teams
Coordinate strategy and execution across Drug Substance, Drug Product, Analytical Development, Regulatory Affairs, Quality Assurance, Global Supply Chain, pilot and commercial manufacturing, and external partners
Identify program risks and develop data‑driven contingencies
Maintain delivery rigor through structured meeting cadences and risk registers
Requirements
Ph.D. in Chemical Engineering, Biomedical Engineering, Pharmaceutics, Pharmaceutical Chemistry, Pharmaceutical Sciences, Chemistry, Biochemistry, Biology, or a related discipline
Lead integrated CMC program for early-stage biologics development and commercialization
Compensation
The salary range for the primary location of this role is: $173,200.00 - $272,600.00
Responsibilities
Lead integrated CMC program for pipeline biologics
Drive strategic and operational alignment across CMC interfaces
Mentor and guide scientists
Support development milestones and regulatory filings
Requirements
Ph.D. in Chemical Engineering, Biomedical Engineering, Pharmaceutics, Pharmaceutical Chemistry, Pharmaceutical Sciences, Chemistry, Biochemistry, Biology, or a related discipline
The role seeks a highly collaborative scientific and matrix leader to lead the Development and Commercialization Team (DCT) for pipeline biologics, moving from candidate selection through early clinical development and First-in-Human (FIH) milestones.
Compensation
$173,200.00 - $272,600.00
Responsibilities
Serve as the Early-Stage Development and Commercialization Team (DCT) Lead for assigned pipeline biologics, holding accountability for integrated CMC development strategy, milestone readiness, and cross-functional alignment.
Lead and operationalize matrixed CMC project teams; establish transparent team structures, functional working groups, clear decision rights, milestone-driven timelines, and escalation pathways.
Drive strategic and operational alignment across key CMC interfaces, including Drug Substance, Drug Product, Analytical Development, Regulatory Affairs, Quality Assurance, Global Supply Chain, Pilot Plant/Commercial Manufacturing, and external partner organizations.
Frame key program decisions, clarify cross-functional trade-offs, identify and mitigate risks, and ensure timely escalation to functional leadership.
Provide drug product leadership and support for relevant early-stage activities, including composition selection, scalable process development, primary packaging/device considerations, compatibility characterization, technology transfer, scale-up, and regulatory filing support.
Seeking an accomplished scientific leader to direct the strategy and execution of biologics drug substance programs, combining cross-functional CMC program leadership with deep expertise in cell line, upstream, and downstream process development to advance biologics through First-in-Human (FIH) milestones.
Compensation
$173,000 - $272,600
Responsibilities
Lead assigned early-stage Development and Commercialization Teams (DCTs), with accountability for integrated CMC strategy, milestone readiness, and advancement through governance decisions.
Establish and lead matrixed CMC teams with clear structures, working groups, decision rights, timelines, escalation paths, and functional accountability.
Coordinate strategy and execution across Drug Substance, Drug Product, Analytical Development, Regulatory Affairs, Quality Assurance, Global Supply Chain, pilot and commercial manufacturing, and external partners.
Identify program risks, evaluate cross-functional trade-offs, develop data-driven contingencies, and provide clear recommendations to senior leaders and governance bodies.
Define phase-appropriate drug substance strategies covering cell line development, upstream and downstream process development, scale-up, technology transfer, and clinical supply.
Principal Scientist, Early DCT LeadMerck · Rahway, US